Solventum Corp (SOLV): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

$2.67B
Year ended 2025-12-31
$2.58B
Trailing 12 months to 2026-06-30
+5.5%
3-year compound annual growth
2022-12-31: $2.27B2023-12-31: $2.25B2024-12-31: $1.59B2025-12-31: $2.67B$2.67B
2022-12-31 EBITDA (USD) 2025-12-31
Period endedEBITDAChange YoYSource filing
2025-12-31$2.67B+67.8%2026-02-27, From 2025-01-01
2024-12-31$1.59B-29.4%2026-02-27, From 2024-01-01
2023-12-31$2.25B-0.8%2026-02-27, From 2023-01-01
2022-12-31$2.27Bn/a2025-02-28, From 2022-01-01

EBITDA at similar companies

Companies with the same SEC industry code (Surgical & Medical Instruments & Apparatus), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedEBITDAChange YoY
Solventum Corp (SOLV)2025-12-31$2.67B+67.8%
Baxter International Inc (BAX)2025-12-31$673.00M-33.4%
ResMed Inc (RMD)2026-06-30$2.09B+10.8%
Dexcom Inc (DXCM)2025-12-31$1.16B+42.3%
Boston Scientific Corp (BSX)2025-12-31$4.98B+28.6%
Becton Dickinson & Co (BDX)2025-09-30$5.04B+7.6%
MiniMed Group, Inc. (MMED)2026-04-24-$34.00Mn/m
West Pharmaceutical Services Inc (WST)2025-12-31$756.30M+4.3%
Globus Medical Inc (GMED)2025-12-31$756.66M+80.4%

Compare SOLV, BAX, RMD, DXCM side by side · Screen every company in Surgical & Medical Instruments & Apparatus ↗